The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. European Group for Serum Tumour Markers in Breast Cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/87846
Title:
The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. European Group for Serum Tumour Markers in Breast Cancer.
Authors:
Robertson, John F R; Jaeger, W; Syzmendera, J J; Selby, C; Coleman, Robert E; Howell, Anthony ( 0000-0002-3879-5991 ) ; Winstanley, J; Jonssen, P E; Bombardieri, Emilio; Sainsbury, J R; Gronberg, H; Kumpulainen, E; Blamey, R
Abstract:
An established biochemical index for monitoring therapy in patients with metastatic breast cancer was tested prospectively in a multicentre study. The index uses two serum tumour markers--carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA15-3) along with erythrocyte sedimentation rate (ESR). 67 patients treated by either endocrine or chemotherapy had CA15-3, CEA and ESR measured at diagnosis of metastases and sequentially during therapy. Two markers, CA15-3 and CEA, were measured on a further 16 patients giving a total of 83 patients who were assessable for CA15-3 and CEA. Of the patients with CA15-3, CEA and ESR measured at diagnosis of metastases 84% (56/67) had elevation of 1 or more markers. During therapy the number with elevated marker(s) rose to 96% (64/67). Changes in the markers were in line with and often pre-dated therapeutic outcome as assessed by the International Union Against Cancer (UICC) criteria both for remission and progression. Patients without elevation of markers on diagnosis subsequently showed a rise in the marker(s) at or before documented disease progression by UICC. The 3 women in whom markers were at no time significantly elevated remain in remission. The results using CA15-3 and CEA were similar but 12% less patients were assessable. CA15-3 and CEA (with and without ESR) provide an objective method to guide therapy in patients with metastatic breast cancer.
Affiliation:
Professional Unit of Surgery, City Hospital, Nottingham, UK. john.robertson@nottingham.ac.uk
Citation:
The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. European Group for Serum Tumour Markers in Breast Cancer. 1999, 35 (1):47-53 Eur. J. Cancer
Journal:
European Journal of Cancer
Issue Date:
Jan-1999
URI:
http://hdl.handle.net/10541/87846
PubMed ID:
10211087
Type:
Article
Language:
en
ISSN:
0959-8049
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorRobertson, John F Ren
dc.contributor.authorJaeger, Wen
dc.contributor.authorSyzmendera, J Jen
dc.contributor.authorSelby, Cen
dc.contributor.authorColeman, Robert Een
dc.contributor.authorHowell, Anthonyen
dc.contributor.authorWinstanley, Jen
dc.contributor.authorJonssen, P Een
dc.contributor.authorBombardieri, Emilioen
dc.contributor.authorSainsbury, J Ren
dc.contributor.authorGronberg, Hen
dc.contributor.authorKumpulainen, Een
dc.contributor.authorBlamey, Ren
dc.date.accessioned2009-12-14T12:27:19Z-
dc.date.available2009-12-14T12:27:19Z-
dc.date.issued1999-01-
dc.identifier.citationThe objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. European Group for Serum Tumour Markers in Breast Cancer. 1999, 35 (1):47-53 Eur. J. Canceren
dc.identifier.issn0959-8049-
dc.identifier.pmid10211087-
dc.identifier.urihttp://hdl.handle.net/10541/87846-
dc.description.abstractAn established biochemical index for monitoring therapy in patients with metastatic breast cancer was tested prospectively in a multicentre study. The index uses two serum tumour markers--carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA15-3) along with erythrocyte sedimentation rate (ESR). 67 patients treated by either endocrine or chemotherapy had CA15-3, CEA and ESR measured at diagnosis of metastases and sequentially during therapy. Two markers, CA15-3 and CEA, were measured on a further 16 patients giving a total of 83 patients who were assessable for CA15-3 and CEA. Of the patients with CA15-3, CEA and ESR measured at diagnosis of metastases 84% (56/67) had elevation of 1 or more markers. During therapy the number with elevated marker(s) rose to 96% (64/67). Changes in the markers were in line with and often pre-dated therapeutic outcome as assessed by the International Union Against Cancer (UICC) criteria both for remission and progression. Patients without elevation of markers on diagnosis subsequently showed a rise in the marker(s) at or before documented disease progression by UICC. The 3 women in whom markers were at no time significantly elevated remain in remission. The results using CA15-3 and CEA were similar but 12% less patients were assessable. CA15-3 and CEA (with and without ESR) provide an objective method to guide therapy in patients with metastatic breast cancer.en
dc.language.isoenen
dc.subjectAntigens, Tumour-Associated, Carbohydrateen
dc.subjectBreast Canceren
dc.subjectCancer Metastasisen
dc.subject.meshAntigens, Tumor-Associated, Carbohydrate-
dc.subject.meshBlood Sedimentation-
dc.subject.meshBreast Neoplasms-
dc.subject.meshCarcinoembryonic Antigen-
dc.subject.meshDisease Progression-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshNeoplasm Metastasis-
dc.subject.meshProspective Studies-
dc.subject.meshRemission Induction-
dc.titleThe objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. European Group for Serum Tumour Markers in Breast Cancer.en
dc.typeArticleen
dc.contributor.departmentProfessional Unit of Surgery, City Hospital, Nottingham, UK. john.robertson@nottingham.ac.uken
dc.identifier.journalEuropean Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.